|
With $14.2bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands.
|
 |
|
The EMA’s CHMP delivered two positive opinions, which will likely see an expansion of Novo Nordisk’s Wegovy offerings in Europe.
|
|
|
The HAE pharmaceutical landscape is set for unprecedented expansion as a large proportion of pipeline drugs are found in Phase III. Emerging technologies such as CRISPR and siRNA platforms may provide meaningful differentiation in an otherwise competitive landscape.
|
|
|
Autobahn expects topline data from the ongoing Phase II AMPLIFY-BD trial in adjunctive bipolar depression in the second quarter of 2026.
|
|
|
Under the agreement, VECOL will act as the primary implementing partner while SK bioscience contributes technology transfer and manufacturing support.
|
|
